The primary endpoint was a change in ALS Functional Rating Scale-Revised (ALSFRS-R) score from baseline to week 28, among participants predicted to have faster disease progression (n = 60), which was based upon SOD1 mutation type and the pre-study ALSFRS-R slope decline. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.